Business Wire

Motorola Expands Indigenous Languages Support With Addition of Ladin

6.6.2024 16:00:00 EEST | Business Wire | Press release

Share

Motorola and the Lenovo Foundation are committed to inclusion and smarter technology for all, and today we reaffirm this dedication with the expansion of our Indigenous Languages Support Initiative. As part of our ongoing efforts to raise awareness and empower Indigenous communities, Motorola is proud to announce the addition of Ladin, a minority language spoken in Italy’s Dolomites region (South of Tyrol), to the list of over 90 languages supported in our smartphones.

United Nations Educational, Scientific and Cultural Organization (UNESCO) estimates that one Indigenous language disappears every two weeks, resulting in the potential loss of around 3,000 unique languages by the end of the century. That’s why over the past three years, Motorola has been at the forefront of this mission, championing the revitalization of endangered languages across the globe.

With a focus on Europe for our latest phase of the Indigenous Languages Support Initiative, Motorola conducted extensive research to identify minority and endangered languages needing support. Among the languages considered, Ladin became a significant candidate, being one of the 12 officially recognized minority languages in Italy and one of three without a kinstate, or entity that is close to the region where their kin-groups reside. With only 30,000 speakers, UNESCO classifies Ladin as an endangered language.

"We've learned over the past few years that it is imperative that we work closely with the community of speakers and scholars that are passionate and committed to saving and promoting the language,” said Janine Oliveira, Executive Director of Software Globalization, Motorola. “This rang true for the Ladin community and made the decision to digitize the language in our devices easy."

Motorola worked alongside the Lenovo Foundation, and several translators and reviewers from the Ladin Institute, Micurá de Rü, led by Professor Paul Videsott, Professor for Romance Philology at the Free University of Bozen-Bolzano (UNIBZ). “This will definitely help Ladin and other minority languages to be more visible,” said Professor Videsott. “Smartphones are like the pencil of the 21st century, and having minority languages, including Ladin, in the motorola edge 50 series, has the same importance of having a language in a book.”

At Motorola, we know indigenous populations are interacting with mobile technology and are one of many diverse groups that make up our valued consumer base. It’s why we started the project, as we aim to preserve human heritage and the unique histories of Indigenous cultures while empowering future generations. But we also believe we have a responsibility to inspire others to do the same. Through June 2024, Motorola has open-sourced over 1 million translated indigenous words, allowing other companies to promote these languages through their interfaces, furthering revitalization efforts worldwide. Today, we’re also excited to share the latest version of our Hello Indigenous whitepaper written in partnership with Lenovo Foundation and UNESCO, serving as a blueprint for others to follow in their footsteps.

Ladin is the latest of several endangered languages that Motorola has added to its smartphone interface, including Kuvi and Kangri (spoken in regions of India), Cherokee (spoken in the United States), Kaingang (spoken in Brazil) and Nheengatu (spoken in the Amazon). Motorola remains committed to our mission of inclusion and cultural preservation, leveraging technology to bridge linguistic divides and foster a more diverse and interconnected world. To access the full data sets for each of our digitized endangered Indigenous languages, please visit: https://www.motorola.com/us/about/endangered-indigenous-languages-data-set.

Legal Disclaimers

Certain features, functionality and product specifications may be network dependent and subject to additional terms, conditions, and charges. All are subject to change without notice. MOTOROLA, the Stylized M Logo, MOTO and the MOTO family of marks are trademarks of Motorola Trademark Holdings, LLC. ©2024 Motorola Mobility LLC. All rights reserved.

About Motorola & Lenovo

Lenovo is a US$57 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a pocket-to cloud portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub. Motorola Mobility LLC was acquired by Lenovo Group Holdings in 2014. Motorola Mobility is a wholly owned subsidiary of Lenovo, and is responsible for designing and manufacturing all Moto and Motorola branded mobile handsets and solutions. To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub and Motorola Global Blog.

About Lenovo Foundation

Lenovo Foundation is the charitable and philanthropic arm of Lenovo, a US$57 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a pocket-to cloud portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cassandra Marrero: marreroc@motorola.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release

Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release

The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release

Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye